pocketful logo light
pocketful logo light
Bayer CropScience Ltd logo

Bayer CropScience Ltd

NSE: BAYERCROP BSE: 506285

₹4327.10

(0.27%)

Mon, 25 May 2026, 09:41 am

mtf coin illustrationMTF 5x

Bayer CropScience Analysis

dividend

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends paid are well covered by earnings (4.2x coverage).
  • Dividends per share have been stable in the past 10 years.
  • Bayer CropScience's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
thumbs up icon

Cons

  • Bayer CropScience's dividend is below the markets top 25% of dividend payers in India (3.08%).

health

thumbs up icon

Pros

  • Bayer CropScience is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Bayer CropScience is profitable, therefore cash runway is not a concern.
  • Bayer CropScience is profitable, therefore cash runway is not a concern.
  • Debt is well covered by operating cash flow (44393.3%, greater than 20% of total debt).
  • Debt is covered by short term assets, assets are 2009.6x debt.
  • Bayer CropScience's cash and other short term assets cover its long term commitments.
  • Interest payments on debt are well covered by earnings (EBIT is 47.9x coverage).
  • Bayer CropScience's level of debt (0.1%) compared to net worth is satisfactory (less than 40%).
thumbs up icon

Cons

  • High level of physical assets or inventory.

management

thumbs up icon

Pros

    thumbs up icon

    Cons

    • The average tenure for the Bayer CropScience board of directors is less than 3 years, this suggests a new board.
    • Duraiswami's remuneration is higher than average for companies of similar size in India.
    • The average tenure for the Bayer CropScience management team is less than 2 years, this suggests a new team.

    misc

    thumbs up icon

    Pros

      thumbs up icon

      Cons

      • Bayer CropScience is not covered by any analysts.
      • Bayer CropScience has significant price volatility in the past 3 months.

      past

      thumbs up icon

      Pros

      • Bayer CropScience's 1-year earnings growth exceeds its 5-year average (100.5% vs -5.1%)
      • Bayer CropScience used its assets more efficiently than the IN Chemicals industry average last year based on Return on Assets.
      • Bayer CropScience has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
      • Bayer CropScience's earnings growth has exceeded the IN Chemicals industry average in the past year (100.5% vs 9.1%).
      thumbs up icon

      Cons

      • Bayer CropScience's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
      • Bayer CropScience has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).

      value

      thumbs up icon

      Pros

      • 506285 outperformed the Chemicals industry which returned 2.2% over the past year.
      • 506285 outperformed the Market in India which returned -14.5% over the past year.
      • BSE:506285 is up 25.9% outperforming the Chemicals industry which returned 6.9% over the past month.
      • BSE:506285 is up 25.9% outperforming the market in India which returned 8% over the past month.
      thumbs up icon

      Cons

      • Bayer CropScience's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
      • Bayer CropScience's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
      • Bayer CropScience is overvalued based on assets compared to the IN Chemicals industry average.
      • Bayer CropScience is overvalued based on earnings compared to the IN Chemicals industry average.
      • Bayer CropScience is overvalued based on earnings compared to the India market.